EGFR and liver disorder: In cases ofpatients with extensive liver disease (>4 nodes) or borderline resectability (wherehigher response rates may lead to a greater possibility of R0 resections), the consensusrecommends individualized discussion in a multidisciplinary environment with the use ofantiangiogenic therapy or anti-EGFR in RAS wild-type cases14,15.